1181215-55-3

Basic information

• Product Name: tert-butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-benzyloxy-pentanoate
• Synonyms: tert-butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-benzyloxy-pentanoate
• CAS NO: 1181215-55-3
• Molecular Weight: 467.562
• Mol File: 1181215-55-3.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-benzyloxy-pentanoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-benzyloxy-pentanoate(1181215-55-3)
• EPA Substance Registry System: tert-butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-benzyloxy-pentanoate(1181215-55-3)

Safety Data

• Hazardous Substances Data: 1181215-55-3(Hazardous Substances Data)

Upstream product

• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 10385-30-5 4-(benzyloxy)butanoic acid 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 169897-87-4 [4S]-4-benzyl-3-(4-benzyloxy-1-butanoyl)-2-oxazolidinone 

Downstream Products

• 1181215-56-4 tert-butyl (R)-3-((S)-4-benzyl-2-oxo-oxazolidine-3-carbonyl)-5-hydroxy-pentanoate 
• 1181215-59-7 C₃₈H₄₅N₅O₆ 
• 1181215-57-5 C₃₄H₃₈N₄O₇ 
• 1181215-58-6 C₃₀H₃₀N₄O₇ 
• 1415685-97-0 (R)-methyl 5-(benzyloxy)-3-(5-(tert-butyldimethylsilyloxy)-1H-indol-2-yl)pentanoate 
• 1415685-99-2 C₃₈H₅₉NO₇Si 
• 1333379-83-1 (R)-methyl 5-(benzyloxy)-3-(5-(triisopropylsilyloxy)-1H-indol-2-yl)pentanoate 
• 1333379-82-0 (R)-5-(benzyloxy)-3-(5-(triisopropylsilyloxy)-1H-indol-2-yl)pentanoic acid 
• 1333379-81-9 (R)-4-tert-butyl 1-methyl 2-(2-(benzyloxy)ethyl)succinate 
• 1333379-80-8 (R)-2-(2-(benzyloxy)ethyl)-4-tert-butoxy-4-oxobutanoic acid 

Relevant articles and documents

TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF

A compound represented by Formula [I]: or pharmaceutically acceptable salt thereof, wherein each symbol is as defined in the description.

Complementary asymmetric routes to (R)-2-(7-hydroxy-2,3-dihydro-1 H-pyrrolo[1,2-a]indol-1-yl)acetate

Two distinct and scalable enantioselective approaches to the tricyclic indole (R)-2-(7-hydroxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetate, an important synthon for a preclinical S1P1 receptor agonist, are reported. Route 1 employs a modified version of Smith's modular 2-substituted indole synthesis as the key transformation. Route 2 involves a highly enantioselective CuH-catalyzed 1,4-hydrosilylation as the stereodefining step. Both routes can be performed without chromatography to provide multigram quantities of the tricycle in ≥98% ee.

PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF

The present invention relates to salts, processes, and process intermediates useful in the preparation of (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid of Formula (Ia), salts, and crystalline forms thereof. The compound (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid has been identified as an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).

MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE

The invention provides compounds inhibitory to the Hepatitis C viral protease, compositions and combinations including the compounds, methods of treatment of conditions wherein inhibition of the Hepatitis C viral protease is medically indicated, and metho